JP2025514858A5 - - Google Patents

Info

Publication number
JP2025514858A5
JP2025514858A5 JP2024563287A JP2024563287A JP2025514858A5 JP 2025514858 A5 JP2025514858 A5 JP 2025514858A5 JP 2024563287 A JP2024563287 A JP 2024563287A JP 2024563287 A JP2024563287 A JP 2024563287A JP 2025514858 A5 JP2025514858 A5 JP 2025514858A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514858A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/061297 external-priority patent/WO2023209177A1/en
Publication of JP2025514858A publication Critical patent/JP2025514858A/ja
Publication of JP2025514858A5 publication Critical patent/JP2025514858A5/ja
Pending legal-status Critical Current

Links

JP2024563287A 2022-04-29 2023-04-28 SARS-CoV-2抗体、及びその使用方法 Pending JP2025514858A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263336332P 2022-04-29 2022-04-29
US63/336,332 2022-04-29
US202263371454P 2022-08-15 2022-08-15
US63/371,454 2022-08-15
PCT/EP2023/061297 WO2023209177A1 (en) 2022-04-29 2023-04-28 Sars-cov-2 antibodies and methods of using the same

Publications (2)

Publication Number Publication Date
JP2025514858A JP2025514858A (ja) 2025-05-09
JP2025514858A5 true JP2025514858A5 (cg-RX-API-DMAC7.html) 2026-05-07

Family

ID=86424696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563287A Pending JP2025514858A (ja) 2022-04-29 2023-04-28 SARS-CoV-2抗体、及びその使用方法

Country Status (22)

Country Link
US (3) US20250289871A1 (cg-RX-API-DMAC7.html)
EP (2) EP4514842B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025514858A (cg-RX-API-DMAC7.html)
KR (1) KR20250006253A (cg-RX-API-DMAC7.html)
CN (1) CN119836433A (cg-RX-API-DMAC7.html)
AU (1) AU2023262192A1 (cg-RX-API-DMAC7.html)
CA (1) CA3256096A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024003259A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015983A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240528A (cg-RX-API-DMAC7.html)
DK (1) DK4514842T3 (cg-RX-API-DMAC7.html)
FI (1) FI4514842T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260789T1 (cg-RX-API-DMAC7.html)
IL (1) IL316481A (cg-RX-API-DMAC7.html)
LT (1) LT4514842T (cg-RX-API-DMAC7.html)
MA (1) MA70469B1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013301A (cg-RX-API-DMAC7.html)
PL (1) PL4514842T3 (cg-RX-API-DMAC7.html)
PT (1) PT4514842T (cg-RX-API-DMAC7.html)
RS (1) RS68251B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600255T1 (cg-RX-API-DMAC7.html)
WO (1) WO2023209177A1 (cg-RX-API-DMAC7.html)

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN102387814A (zh) 2009-01-29 2012-03-21 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
WO2021195418A1 (en) * 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
PH12022553106A1 (en) 2020-05-17 2023-11-20 Astrazeneca Uk Liimited Sars-cov-2-antibodies and methods of selecting and using the same
IL300257A (en) 2020-08-10 2023-03-01 Astrazeneca Uk Ltd SARS-COV-2 antibodies for the treatment and prevention of COVID-19
US20240043507A1 (en) 2021-02-04 2024-02-08 Rq Biotechnology Limited Antibodies
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防covid—19之組成物
WO2023084055A1 (en) 2021-11-12 2023-05-19 Rq Biotechnology Limited Compositions
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體

Similar Documents

Publication Publication Date Title
KR102340832B1 (ko) 항 pd-1 항체 및 그의 용도
KR102876923B1 (ko) 항-il-2 항체 및 조성물 및 이의 용도
US11117954B2 (en) Antibodies specifically binding to zika virus epitopes and uses thereof
CN105814081B (zh) 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
JP2021526022A5 (cg-RX-API-DMAC7.html)
JP7766392B2 (ja) 治療用抗cd40リガンド抗体
HK1216428A1 (zh) 血小板衍生生长因子b之特异性抗体及其组合物和用途
TWI776808B (zh) 干擾素β抗體及其用途
EP2318442A1 (en) Treatment of autoimmune and inflammatory disease
EP3858857A1 (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
TW202146451A (zh) 抗人類cd19抗體
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
CN115515976A (zh) 冠状病毒抗体
CN113015745A (zh) 针对金黄色葡萄球菌白细胞毒素的抗体
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
WO2025246679A1 (zh) 一种广谱中和冠状病毒的抗体及其应用
EP3126391B1 (en) Antibodies against hpa-1a
JP2014526886A (ja) マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体
KR101828794B1 (ko) 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 항체
WO2018088850A2 (ko) Cd40에 특이적으로 결합하는 항체 및 그의 용도
TW202144005A (zh) 一種抗ox40抗體醫藥組成物及其用途
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
IL292757A (en) Anti-tigit antibodies and uses thereof
JP2022527790A5 (cg-RX-API-DMAC7.html)